Laura Book
@LauraJBook
Followers
752
Following
8K
Media
88
Statuses
5K
Former SEO, SEM, Social Media and Internet Marketing Afficionado, now a lung cancer advocate/patient
Washington, USA
Joined January 2008
RT @EGFRResisters: Osimertinib plus chemotherapy versus osimertinib for patients with advanced NSCLC with concomitant EGFR and TP53 mutatio….
0
14
0
This is shameful and NOT beautiful! @realDonaldTrump & Republicans are destroying our country and putting all its people at risk.
How many people will lose health care in YOUR state under Trump's "Big Beautiful Bill"?. • Alabama – 219,803.• Alaska – 39,989.• Arizona – 365,984.• Arkansas – 158,745.• California – 2,368,466.• Colorado – 240,953.• Connecticut – 86,580.• Delaware – 54,957.• Florida –.
0
0
1
We need Medicare to approve AI as a 2nd eye in medical imaging.
#HawaiiLung25 @PatelOncology @UCSDHealth discusses how #AI can transform cancer care- opportunities and pitfalls .👍⬇️documentation workload (ambient AI), ⬆️clinical trial efficiency , ⬆️improve patient communication (chatbots).⚠️caution for errors in AI conclusions.(drunken
0
0
1
Thank you for doing all you do. This disease is relentless and needs better treatments. Research is key! 💔.
Lung cancer took the life of another one of my patients today, only 48. A Veteran. Spirit unbreakable, great sense of humor. Despite advances, another reminder of the need for more progress as research funding gets thinner. Where do we go? How do we get there?.
0
1
7
Thank you, @LAGurwitch for advocating for chronically ill and cancer patients who get financially gaslighted by healthcare insurers, PBMs and the like. Make it right!!
0
0
1
this woke me up!!!! When is aumolertinib coming to US and how does it rank in same realm with other TKIs???.
2
0
6
As a patient, it may be better than docetaxel but still meh. We need a higher bar.
FDA grants accelerated approval for datopotamab deruxtecan, anti-TROP2 ADC, for #EGFR mutant NSCLC after prior TKI and chemotherapy. An active agent, based on TROPION-Lung01 and 05. Important toxicities include stomatitis and ocular effects.
0
0
4
RT @jillfeldman4: If your time has value, then so does ours. And if our ideas are critical enough to shape your work, they’re critical enou….
0
15
0
RT @EGFRResisters: The EGFR Resisters June Newsletter is here: ASCO 2025 Research Highlights, New Project PRIORITY Dashboard, and news from….
0
2
0
We now definitely know who owns ABC News (and CBS too): ABC News Suspends Terry Moran Over X Post That Called Trump Official Stephen Miller A “World-Class Hater”
0
0
1
RT @chulkimMD: Savolitinib + osimertinib shows ORR (58% vs 16%), DoR (11.8 vs 4.5 mo), and PFS (8.3 vs 3.6 mo) vs. savolitinib + placebo in….
0
16
0
Not a very impressive ORR.
ABBV-400 a new antiMET ADC tested in pretreated EGFRm NSCLC reported ORR 26% and DoR 9.8 regardless cMET expression. It is a crowded space with BL-B01D1, DB-1310, dual TKI EGFR/ET etc. Can we ⬆️ ABBV-400 combining with osimertinib?TelisoV + Osi > Teliso alone in mEGFR 🫁#ASCO25
0
2
1
As a cancer patient, I would rather have aa additional eye (AI) looking at my pathology and reading my scans than just two human eyes. Things are missed!.
Are pigeons going to take pathologists jobs? AI in oncology and therapeutics. Last session of first day #ASCOBT19 @asco @oncoalert Gregory Sorensen
0
1
4
RT @jennifermarksmd: So important to remember - continuation of pemetrexed maintenance on the #FLAURA2 likely is required to derive benefit….
0
14
0
RT @LUNGevity: Great to see progress in non-classical EGFRm #NSCLC too. More studies are needed. #ASCO25 @EGFRResisters.
0
5
0
RT @JordiRemon: DB-1310 is a new ADC anti-HER3 with pantumor activity including NSCLC with promising activity in EGFRm 🫁. Based on disappoi….
0
15
0
Cancer patients want durable and effective treatments but not necessarily at expense of quality of life and nasty toxicities.
How to choose the appropriate first line option for #egfr mutated #NSCLC opening presentation from Dr Jessica Bauman. Excellent points on what matters to clinicians and (more importantly) patients. #ASCO2025
0
4
14
In this new Trump age, it's important to show our appreciation for cancer researchers. They are extending our lives and bringing hope to cancer survivors!.
@IMG_Oncologists .Thrilled to be part of #ASCO2025, contributing to six posters—including one as first author! #OnlinePublication #BsAbs #SolidTumors.Grateful to @ADesaiMD for your outstanding mentorship & this incredible opportunity. It was a pleasure collaborating with @Larvol.
0
0
0